246 related articles for article (PubMed ID: 22211510)
21. A Follow-Up Study of the Prevalence of Valvular Heart Abnormalities in Hyperprolactinemic Patients Treated With Cabergoline.
Drake WM; Stiles CE; Bevan JS; Karavitaki N; Trainer PJ; Rees DA; Richardson TI; Baldeweg SE; Stojanovic N; Murray RD; Toogood AA; Martin NM; Vaidya B; Han TS; Steeds RP; ; Baldeweg FC; Sheikh UE; Kyriakakis N; Parasuraman SK; Taylor L; Butt N; Anyiam S
J Clin Endocrinol Metab; 2016 Nov; 101(11):4189-4194. PubMed ID: 27571182
[TBL] [Abstract][Full Text] [Related]
22. A comparison of cabergoline and bromocriptine on the risk of valvular heart disease in patients with prolactinomas.
Boguszewski CL; dos Santos CM; Sakamoto KS; Marini LC; de Souza AM; Azevedo M
Pituitary; 2012 Mar; 15(1):44-9. PubMed ID: 21847572
[TBL] [Abstract][Full Text] [Related]
23. No evidence of a detrimental effect of cabergoline therapy on cardiac valves in patients with acromegaly.
Maione L; Garcia C; Bouchachi A; Kallel N; Maison P; Salenave S; Young J; Assayag P; Chanson P
J Clin Endocrinol Metab; 2012 Sep; 97(9):E1714-9. PubMed ID: 22723314
[TBL] [Abstract][Full Text] [Related]
24. Cabergoline use for pituitary tumors and valvular disorders.
Auriemma RS; Pivonello R; Ferreri L; Priscitelli P; Colao A
Endocrinol Metab Clin North Am; 2015 Mar; 44(1):89-97. PubMed ID: 25732645
[TBL] [Abstract][Full Text] [Related]
25. Dopamine agonists and valvular heart disease.
Cheung D; Heaney A
Curr Opin Endocrinol Diabetes Obes; 2009 Aug; 16(4):316-20. PubMed ID: 19506475
[TBL] [Abstract][Full Text] [Related]
26. The cabergoline-resistant prolactinoma patient: new challenges.
Molitch ME
J Clin Endocrinol Metab; 2008 Dec; 93(12):4643-5. PubMed ID: 19056842
[No Abstract] [Full Text] [Related]
27. The risks of medical treatment of prolactinoma.
Castinetti F; Albarel F; Amodru V; Cuny T; Dufour H; Graillon T; Morange I; Brue T
Ann Endocrinol (Paris); 2021 Feb; 82(1):15-19. PubMed ID: 33373604
[TBL] [Abstract][Full Text] [Related]
28. Cabergoline use and risk of fibrosis and insufficiency of cardiac valves. Meta-analysis of observational studies.
De Vecchis R; Esposito C; Ariano C
Herz; 2013 Dec; 38(8):868-80. PubMed ID: 23743769
[TBL] [Abstract][Full Text] [Related]
29. Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease.
Wakil A; Rigby AS; Clark AL; Kallvikbacka-Bennett A; Atkin SL
Eur J Endocrinol; 2008 Oct; 159(4):R11-4. PubMed ID: 18625690
[TBL] [Abstract][Full Text] [Related]
30. A cross-sectional study of the prevalence of cardiac valvular abnormalities in hyperprolactinemic patients treated with ergot-derived dopamine agonists.
Drake WM; Stiles CE; Howlett TA; Toogood AA; Bevan JS; Steeds RP;
J Clin Endocrinol Metab; 2014 Jan; 99(1):90-6. PubMed ID: 24187407
[TBL] [Abstract][Full Text] [Related]
31. Heart abnormalities in Parkinson patients after discontinuation or continuation of ergot-derived dopamine agonists: a treatment-blinded echocardiographic study.
Rasmussen VG; Poulsen SH; Dupont E; Østergaard K; Safikhany G; Egeblad H
J Heart Valve Dis; 2009 Jul; 18(4):463-9. PubMed ID: 19852154
[TBL] [Abstract][Full Text] [Related]
32. Cabergoline and the risk of valvular lesions in endocrine disease.
Lancellotti P; Livadariu E; Markov M; Daly AF; Burlacu MC; Betea D; Pierard L; Beckers A
Eur J Endocrinol; 2008 Jul; 159(1):1-5. PubMed ID: 18456868
[TBL] [Abstract][Full Text] [Related]
33. Heart valve disease associated with treatment with ergot-derived dopamine agonists: a clinical and echocardiographic study of patients with Parkinson's disease.
Rasmussen VG; Poulsen SH; Dupont E; Østergaard K; Safikhany G; Egeblad H
J Intern Med; 2008 Jan; 263(1):90-8. PubMed ID: 18036161
[TBL] [Abstract][Full Text] [Related]
34. Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline.
Lafeber M; Stades AM; Valk GD; Cramer MJ; Teding van Berkhout F; Zelissen PM
Eur J Endocrinol; 2010 Apr; 162(4):667-75. PubMed ID: 20071478
[TBL] [Abstract][Full Text] [Related]
35. Valvular Dysfunction in Lymphoma Survivors Treated With Autologous Stem Cell Transplantation: A National Cross-Sectional Study.
Murbraech K; Wethal T; Smeland KB; Holte H; Loge JH; Holte E; Rösner A; Dalen H; Kiserud CE; Aakhus S
JACC Cardiovasc Imaging; 2016 Mar; 9(3):230-9. PubMed ID: 26897666
[TBL] [Abstract][Full Text] [Related]
36. [Dopamin agonist treatment and fibrotic heart valve disease in hyperprolactinaemia patients].
Steffensen C; Mægbæk ML; Laurberg P; Andersen M; Kistorp C; Nørrelund H; Dal J; Jørgensen JO
Ugeskr Laeger; 2014 Jan; 176(1):58-60. PubMed ID: 24629610
[TBL] [Abstract][Full Text] [Related]
37. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease.
Antonini A; Poewe W
Lancet Neurol; 2007 Sep; 6(9):826-9. PubMed ID: 17706566
[TBL] [Abstract][Full Text] [Related]
38. Valvular heart disease in Parkinson's disease patients treated with dopamine agonists: a reader-blinded monocenter echocardiography study.
Junghanns S; Fuhrmann JT; Simonis G; Oelwein C; Koch R; Strasser RH; Reichmann H; Storch A
Mov Disord; 2007 Jan; 22(2):234-8. PubMed ID: 17094087
[TBL] [Abstract][Full Text] [Related]
39. Cardiac valvular abnormalities associated with use and cumulative exposure of cabergoline for hyperprolactinemia: the CATCH study.
Budayr A; Tan TC; Lo JC; Zaroff JG; Tabada GH; Yang J; Go AS
BMC Endocr Disord; 2020 Feb; 20(1):25. PubMed ID: 32075620
[TBL] [Abstract][Full Text] [Related]
40. Clinical Review#: Potential cardiac valve effects of dopamine agonists in hyperprolactinemia.
Valassi E; Klibanski A; Biller BM
J Clin Endocrinol Metab; 2010 Mar; 95(3):1025-33. PubMed ID: 20130078
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
